These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11586272)

  • 1. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.
    Miller JL; Petteway SR; Lee DC
    J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S91-4. PubMed ID: 11586272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
    Kempf C; Stucki M; Boschetti N
    Biologicals; 2007 Mar; 35(1):35-42. PubMed ID: 16581263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.
    Cai K; Gierman TM; Hotta J; Stenland CJ; Lee DC; Pifat DY; Petteway SR
    BioDrugs; 2005; 19(2):79-96. PubMed ID: 15807628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
    Lee DC; Miller JL; Petteway SR
    Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with the viral safety of immunoglobulins.
    Hellstern P
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulins: clinical experience and viral safety.
    Ballow M
    J Am Pharm Assoc (Wash); 2002; 42(3):449-58; quiz 458-9. PubMed ID: 12030632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
    Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
    Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality Control Testing for Tracking Endotoxin-Producing Gram-Negative Bacteria during the Preparation of Polyvalent Snake Antivenom Immunoglobulin.
    Sheraba NS; Diab MR; Yassin AS; Amin MA; Zedan HH
    PDA J Pharm Sci Technol; 2015; 69(4):499-510. PubMed ID: 26242786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Premium Quality Plasma-derived IVIg (IQYMUNE
    Paolantonacci P; Appourchaux P; Claudel B; Ollivier M; Dennett R; Siret L
    PDA J Pharm Sci Technol; 2018; 72(2):176-187. PubMed ID: 29158287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus safety of intravenous immunoglobulin: future challenges.
    Boschetti N; Stucki M; Späth PJ; Kempf C
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):333-44. PubMed ID: 16391410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of vegetable-derived tween 80 for virus inactivation by solvent/detergent treatment.
    Roberts P; Sims G
    Biologicals; 1999 Sep; 27(3):263-4. PubMed ID: 10652181
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro evaluation of the biological activities of IgG in seven Chinese intravenous immunoglobulin preparations.
    Ye S; Li D; Liu F; Lei M; Jiang P; Wang Z; Zhang R; Du X; Cao H; Ma L; Li C
    J Pharm Biomed Anal; 2018 Mar; 151():317-323. PubMed ID: 29413980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research and development commitments in an integrated plasma collection and plasma fractionation environment.
    Radosevich M
    Semin Thromb Hemost; 1998; 24(2):157-61. PubMed ID: 9579637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse reactions and pathogen safety of intravenous immunoglobulin.
    Carbone J
    Curr Drug Saf; 2007 Jan; 2(1):9-18. PubMed ID: 18690945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.